Lumenis to Introduce UltraPulse® SCAAR FX™ to the European Plastic Surgery Market at the International Society for Burn Injuries (ISBI)
Fractional CO2 Laser Impacts Four Times Deeper Than Other CO2 Lasers
Edinburgh, Scotland (PRWEB) September 07, 2012
Lumenis Ltd., the world’s largest medical laser company which develops, manufactures and distributes a broad range of medical lasers and sophisticated energy delivery equipment for surgical, aesthetic and ophthalmic applications, announces its participation at the 16th International Society for Burn Injuries (ISBI) to be held in Edinburgh, Scotland on September 9-13, 2012.
At ISBI, Lumenis will showcase UltraPulse´s unique SCAAR FX (Synergistic Coagulation and Ablation for Advanced Resurfacing) mode. SCAAR FX enables the treatment of surgical and acne scars, commonly characterized as conspicuous, complex and deep skin lesions, which require synergistic coagulation and ablation for advanced resurfacing. Treatments with SCAAR FX have shown remarkable results and minimal side effects. Using precision and high energy impact (up to 150 mJ per pulse per spot), SCAAR FX allows direct impact up to four millimeters deep into the skin tissue, four times deeper than other CO2 lasers.
Using a unique ablation/coagulation ratio, UltraPulse with SCAAR FX was designed to substantially improve structure of deep contracted skin lesions, such as surgical scars. This leads to increased range of motion in these areas and enhanced skin appearance. Other CO2 lasers on the market only reach a depth of approximately one millimeter per pulse, and are limited by less than optimum ablation/coagulation ratios, which may lead to unsatisfactory results.
According to Dr. Matteo Tretti Clementoni, plastic surgeon at the Department of Dermatological Surgery and Laser Institute Europeo, Milan, Italy, “With SCAAR FX, I am able to treat deep skin conditions, like hypertrophic scars, with the results of enhanced skin condition (appearance) and improved quality of life (function) for patients with these types of deep lesions. UltraPulse´s SCAAR FX with a very high ablated tissue/ablated surface ratio, short pulse duration and high energy per pulse allows me to perform a deep, precise treatment, achieving a regression of these scars.”
“Our physician partners who are using UltraPulse with SCAAR FX are reporting that they are able to offer a significantly better quality of life for their patients with deep skin lesions, such as conspicuous scars,” said Rami Sharon, Lumenis´ regional president of EMEA.
Lumenis will be presenting SCAAR FX at Booth Number 5 in Cromdale Hall, Edinburgh International Conference Centre (EICC).
Free Paper Sessions to note, taking place on September 11 at 13:30-15:00:
- Dr. Matteo Tretti Clementoni and Dr. Tapan Patel
“Burn scar treatment with a new UltraPulse fractional CO2 laser: a preliminary clinical report.”
- Dr. Marco Palombo, St. Euginio Hospital, Rome, Italy
“A new protocol for burn and post-traumatic scars treatment”
“The role of lasers in the management of the healing processes and their outcomes.”
For more information on UltraPulse, contact Lumenis or visit http://www.lumenis.com.
Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an installed base of over 80,000 systems and a presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning ”Light of Life” highlighting the light – the basis of our technologies – used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.
For further information contact:
Director, Global Marketing Communications
Lumenis® and the Lumenis logo are trademarks or registered trademarks of Lumenis.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9879727.htm